| Literature DB >> 24085547 |
Abstract
Local protein synthesis has been demonstrated in the peripheral processes of sensory primary afferents and is thought to contribute to the maintenance of the neuron, to neuronal plasticity following injury and also to regeneration of the axon after damage to the nerve. The mammalian target of rapamycin (mTOR), a master regulator of protein synthesis, integrates a variety of cues that regulate cellular homeostasis and is thought to play a key role in coordinating the neuronal response to environmental challenges. Evidence suggests that activated mTOR is expressed by peripheral nerve fibers, principally by A-nociceptors that rapidly signal noxious stimulation to the central nervous system, but also by a subset of fibers that respond to cold and itch. Inhibition of mTOR complex 1 (mTORC1) has shown that while the acute response to noxious stimulation is unaffected, more complex aspects of pain processing including the setting up and maintenance of chronic pain states can be disrupted suggesting a route for the generation of new drugs for the control of chronic pain. Given the role of mTORC1 in cellular homeostasis, it seems that systemic changes in the physiological state of the body such as occur during illness are likely to modulate the sensitivity of peripheral sensory afferents through mTORC1 signaling pathways.Entities:
Keywords: itch; local translation; nociceptors; pain; the mammalian target of rapamycin complex 1 (mTORC1)
Mesh:
Substances:
Year: 2013 PMID: 24085547 PMCID: PMC4237183 DOI: 10.1002/dneu.22133
Source DB: PubMed Journal: Dev Neurobiol ISSN: 1932-8451 Impact factor: 3.964
Figure 1Distribution of activated mTOR (P-mTOR) immunoreactivity in peripheral sensory nerve fibers in the rodent cutaneous tissue. (A–F and J–L) Confocal images of 40 μm thick frozen sections cut perpendicular to the plantar surface of the rodent hindpaw. (A–C) Arrows indicates co-localization of P-mTOR (green) and a general marker of sensory nerve fibers PGP (red) in the footpad of rat. Arrow heads indicate a fine fiber (most likely a C-fiber) entering the epidermis but not P-mTOR positive. Scale bar = 70 μm. Modified from Jimenez et al. (2008). (D–F) Confocal images of a nerve bundle in the dermis co-stained with P-mTOR (green) and an A-fiber marker N52 (red). Note that all P-mTOR positive fibers are stained but that not all A-fibers are co-labeled. Scale bar = 15 μm. (G–I) Confocal images of rat lumbar DRG stained with P-mTOR (green) and gastrin-releasing peptide, a marker of itch fibers (GRP, red). Note the small size of the cell body and the extension of P-mTOR immunoreactivity into the proximal axon (arrow). Scale bar = 15 μm. (J–L) Confocal images of a bundle of nerve fibers in the dermis of mouse cutaneous tissue stained for P-mTOR (green) and TRPM8-GFP (red) showing some co-expression (arrow). Scale bar = 15 μm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2(A) Rapamycin increases A- but not C-nociceptor-evoked paw withdrawal thresholds. Time-course effects of rapamycin or appropriate vehicle, on paw withdrawal thresholds to fast and slow heat ramps that preferentially activate A- and C-nociceptors, respectively. Vertical dashed line indicates the drug injection time. *P < 0.05. Reproduced from Jimenez-Diaz et al. (2008). (B–D) In the spared nerve injury (SNI) model of neuropathic pain, intraperitoneal (i.p.) administration of rapamycin analogue CCI-779 did not affect acute pain in sham mice but attenuated mechanical (upper panel) and cold (lower panel) hypersensitivity in neuropathic mice (B–C). Note that local CCI-779 had a similar effect (Obara et al., 2011). (D) Also in carrageenan-induced inflammation i.p. injection of CCI-779 produced a transient reduction in mechanical thresholds but did not affect response to heat. Effects of i.p. injection of CCI-779 (25 mg/kg) or vehicle in sham-treated (B), SNI-treated (C), or carrageenan-treated (D) mice on the mechanical withdrawal threshold measured with von Frey filaments (B–D, upper panel), response to cold measured by withdrawal duration to the acetone drop test (B-C, lower panel), and withdrawal latency to heat measured by the Hargreaves test (D, lower panel). The measurements were assessed before injury as basal pain threshold (BS) and then 3 days (sham and SNI) or 12 h (carrageenan) after the injury (time point 0). The effect of CCI-779 was assessed 2, 4, 6, and 24 h after i.p. injection. Arrows indicate CCI-779/vehicle injection time. *P < 0.05. This figure has been reproduced with permission of the International Association for the Study of Pain® (IASP). The figure may NOT be reproduced for any other purpose without permission.